Cybin D/B/A Helus Pharma HELP
9.03 USD 0.00 (+0.00%)
At closeNov 4, 2026, 9:12 AM EST
9.33 +0.30 +3.32%
Pre-market · Nov 4, 9:12 AM ET
8.94 Day range 9.57
3.76 52-week range 15.15
- YTD
- +10.39%
- 1 year
- +46.35%
- Market cap
- 659.82M
- EPS (ttm)
- -4.15
- Shares out
- 73.06M
- Forward P/E
- -7.55
- YTD return
- +10.39%
- 1-year return
- +46.35%
- Volume
- 1.23M
- Avg volume
- 1.71M
- Open
- 9.11
- Previous close
- 9.03
- Day's range
- 8.94 – 9.57
- 52-week range
- 3.76 – 15.15
- Beta
- 0.63
- Analysts
- Strong Buy
- Price target
- 40.24 (+345.7%)
- Earnings date
- Nov 12, 2026
5D -1.33 (-13.23%)
Key statistics
- Enterprise value
- 831.64M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -82.43M
- Total cash
- 166.36M
- Total debt
- 0
- Return on equity
- -86.94%
- Short % of float
- 0.00%
- 50-day average
- 10.70
- 200-day average
- 7.11
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 40.24 +345.7% upside
Now 9.03
- Target (low)
- 15.08
- Target (mean)
- 40.24
- Target (high)
- 69.16
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy1
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.9448.
Financials — quick view
HELP Revenue — quarterly 0
HELP Net income — quarterly -47.82M
HELP EPS — quarterly -0.91
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.67 | — | — | — |
| Aug 14, 2026 | Jun 30, 2026 | -0.83607 | -0.91 | -0.07 | -8.84% |
| Jun 30, 2026 | Mar 31, 2026 | -1.04 | -0.95583 | +0.08 | +8.09% |
| Feb 13, 2026 | Dec 31, 2025 | -0.53 | -0.99243 | -0.46 | -87.25% |
| Nov 13, 2025 | Sep 30, 2025 | -0.74 | -1.39 | -0.65 | -87.84% |
| Aug 13, 2025 | Jun 30, 2025 | -0.95779 | -1.10 | -0.14 | -14.72% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2026 | Barclays | init | — | Overweight |
| Aug 20, 2026 | TD Cowen | main | Buy | Buy |
| Jul 27, 2026 | Wells Fargo | init | — | Overweight |
| Jul 9, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 1, 2026 | Canaccord Genuity | main | Buy | Buy |
| Apr 13, 2026 | TD Cowen | init | — | Buy |
About Cybin D/B/A Helus Pharma
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- helus.com
News
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference 
Helus Pharma Appoints Mark Lawson As Board Chair, Effective Immediately 
Wells Fargo Maintains Overweight on Helus Pharma, Raises Price Target to $22 
Cybin Inc. To Officially Change Name To Helus Pharma Inc. Effective October 1, 2026 
Helus Pharma Presents Four Posters Evaluating HLP003 To Treat Major Depressive Disorder At Psych Congress 2026 
9 Health Care Stocks Whale Activity In Today’s Session 
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket 
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs 
TD Cowen Maintains Buy on Helus Pharma, Raises Price Target to $62 - Helus Pharma Q1 EPS $(0.91) Beats $(1.07) Estimate
Your note
Sign in to keep a note on HELP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Bartlone (Aaron Frank) | Senior Officer of Issuer | Acquisition or disposition in the public market | Sep 1, 2026 | 225,154 |
| Cavers (Gregory Joseph) | Senior Officer of Issuer | Acquisition or disposition in the public market | Sep 1, 2026 | 125,937 |
| Fahel (Gabriel) | Senior Officer of Issuer | Acquisition or disposition in the public market | Sep 14, 2026 | 102,958 |
| Froese (Grant B.) | Director of Issuer | Exercise of rights | Aug 31, 2026 | 0 |
| Glavine (Paul) | Director of Issuer | Acquisition or disposition in the public market | Sep 7, 2026 | 4,247,694 |
| Hoskins (Eric William) | Director of Issuer | Exercise of rights | Aug 31, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Venrock Adviser, LLC | 4.89% | 3,851,654 | 52.81M | Jun 29, 2026 |
| Orbimed Advisors LLC. | 4.16% | 3,271,400 | 44.85M | Jun 29, 2026 |
| Adage Capital Partners GP L.L.C. | 3.89% | 3,060,000 | 41.95M | Jun 29, 2026 |
| Millennium Management Llc | 3.34% | 2,632,156 | 36.09M | Jun 29, 2026 |
| Rosalind Advisors, Inc. | 2.49% | 1,956,814 | 26.83M | Jun 29, 2026 |
| Sphera Funds Management Ltd. | 2.06% | 1,620,753 | 22.22M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.47% | 367,432 | 5.04M | Aug 30, 2026 |
| ROYCE FUND-Royce Smaller-Companies Growth Fund | 0.29% | 232,000 | 3.18M | Jun 29, 2026 |
| Invesco Exch-Trd Fd. TRT II-Invesco NASDAQ Future Gen 200 ETF | 0.03% | 24,576 | 336.94K | Jul 30, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.02% | 15,991 | 219.24K | Jul 30, 2026 |
| TIFF INVESTMENT PROGRAM-TIFF Multi-Asset Fund | 0.00% | 1,804 | 24.73K | Jun 29, 2026 |